High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study-Reference-Cited by-同舟云学术

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study

Published:2015-11-26 Issue:2 Volume:10 Page:310-319
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Petersen Tess,Townsend Kerry,Gordon Lori A.,Sidharthan Sreetha,Silk Rachel,Nelson Amy,Gross Chloe,Calderón Monica,Proschan Michael,Osinusi Anu,Polis Michael A.,Masur Henry,Kottilil Shyam,Kohli Anita

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-015-9680-7.pdf

Reference30 articles.

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.

2. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–1605.

3. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.

4. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523.

5. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. New Engl J Med. 2014;370:222–232.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence in Hepatitis C Virus Treatment: What We Know;Seminars in Liver Disease;2024-04-24

2. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study;BMC Infectious Diseases;2024-02-23

3. Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World Study;Advances in Therapy;2023-06-07

4. Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021;Hepatology Communications;2023-03-30

5. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry;Hepatology International;2023-03-27